A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council Investigation.
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003523:Cycloserine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage*; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D006723:Hong Kong; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011718:Pyrazinamide / Q000627:therapeutic use; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D012293:Rifampin